Table of contents
This medicine is now withdrawn from use in the European Union.
The marketing authorisation for Lifmior has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
Lifmior : EPAR - Summary for the public (PDF/667.44 KB)
First published: 13/03/2017
Last updated: 20/02/2020
This EPAR was last updated on 20/02/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Pfizer Europe MA EEIG
|Date of issue of marketing authorisation valid throughout the European Union||
Boulevard de la Plaine 17
05/04/2019 Lifmior - EMEA/H/C/004167 - IG/1082
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
- Rheumatoid arthritis;
- Juvenile idiopathic arthritis
- Psoriatic arthritis;
- Axial spondyloarthritis;
- Plaque psoriasis;
- Paediatric plaque psoriasis.